SOMERSET, N.J., July 19, 2010 (GLOBE NEWSWIRE) -- Tamir Biotechnology, Inc. (formerly Alfacell Corporation) (OTCBB:ACEL) announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) confirmed that testing of three (3) of the company's compounds Onconase® (Ranpirnase), Natural P31, and Recombinant Amphinase 2 showed in vitro results rarely seen before by the U.S. government for the Dengue virus.
